Full Press Release Details
CureVac Appoints International Financial Expert
/ BOSTON, USA - June 20, 2023 - CureVac N.V. (Nasdaq: CVAC) ("CureVac"), a global biopharmaceutical company
developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the appointment
of Michael Brosnan as an independent director to the company's Supervisory Board. Mr. Brosnan replaces Hans Christoph Tanner, who has
been a member of CureVac's Supervisory Board since 2015. Michael Brosnan was appointed at CureVac's Annual General Meeting on June
"Michael is an excellent addition to the
CureVac board. His global financial and audit experience will help manage financial stability as we move towards late-stage clinical
development and commercialization," said Jean St phenne, Chairman of CureVac's Supervisory Board. "We would
like to extend our wholehearted thanks to Hans Christoph for his dedication and guidance for the past eight years and wish him the very
best for the future."
Mr. Brosnan is a highly regarded international
financial expert, with extensive experience in executive and non-executive financial board roles and as an auditor. He currently serves
as a member of the supervisory board and chairman of the audit committee at MorphoSys AG. He also is a member of the supervisory board
and chairman of the audit Committee of Daimler Truck AG. Until his retirement in 2019, he was the CFO of Fresenius Medical Care Management
AG. Prior to taking over management roles in financial departments, he was an audit partner at KPMG. Mr. Brosnan holds a degree in business
administration and accounting from Northeastern University, Boston.
"CureVac is a pioneer in the mRNA field,
and I'm delighted to join the company at a time of exceptional growth and progress," said Mr. Brosnan. "I look forward
to working with my fellow Supervisory Board members and the executive team to help deliver on the promise of this transformative technology."
CureVac (Nasdaq: CVAC) is a global biopharmaceutical
company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing
this versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of optimized
mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July
2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based
on CureVac's second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19
vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline
across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has
its headquarters in T bingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium,
Switzerland and the U.S. Further information can be found at www.curevac.com.
CureVac Media and Investor Relations Contact
Fakih, Vice President Corporate Communications and Investor Relations
Forward-Looking Statements CureVac
This press release contains statements that
constitute "forward looking statements" as that term is defined in the United States Private Securities Litigation
Reform Act of 1995, including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or
projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss
AG, CureVac Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the
"company") regarding future events or future results, in contrast with statements that reflect historical facts.
Examples include statements regarding the completion, size and terms of the proposed public offering. In some cases, you can
identify such forward-looking statements by terminology such as "anticipate," "intend,"
"believe," "estimate," "plan," "seek," "project," or
"expect," "may," "will," "would," "could," "potential,"
"intend," or "should," the negative of these terms or similar expressions. Forward-looking statements are
based on management's current beliefs and assumptions and on information currently available to the company. However, these
forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such
statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative
worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding,
ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory
approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any
products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing
competition and consolidation in the company's industry, the effects of the COVID-19 pandemic on the company's business
and results of operations, ability to manage growth, reliance on key personnel, reliance on intellectual property protection,
ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors.
Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such
statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially
from those it thought would occur. The forward-looking statements included in this press release are made only as of the date
hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.
For further information, please reference the company's reports and documents filed with the U.S. Securities and Exchange
Commission (SEC). You may get these documents by visiting EDGAR on the SEC website at www.sec.gov.